Torque Therapeutics Announces the Appointment of John Cox as Chief Executive Officer
Retrieved on:
Wednesday, October 2, 2019
Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primed adoptive cell transfer therapeutics with uniquely broad potential to treat patients with a wide range of hematologic and solid malignancies, announced the appointment of John Cox as Chief Executive Officer.
Key Points:
- Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primed adoptive cell transfer therapeutics with uniquely broad potential to treat patients with a wide range of hematologic and solid malignancies, announced the appointment of John Cox as Chief Executive Officer.
- Douglas Cole, Lead Director of Torque and Managing Partner at Flagship Pioneering, said, I am thrilled that John has taken on the role of CEO of Torque.
- Mr. Cox was most recently Chief Executive Officer of Bioverativ.
- I am delighted to take leadership of Torque Therapeutics, Mr. Cox said.